Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001351984 | SCV001546501 | uncertain significance | Bardet-Biedl syndrome; McKusick-Kaufman syndrome | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with lysine at codon 422 of the MKKS protein (p.Arg422Lys). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and lysine. This variant is present in population databases (rs754555322, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with MKKS-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV004734141 | SCV005365017 | uncertain significance | MKKS-related disorder | 2024-02-06 | no assertion criteria provided | clinical testing | The MKKS c.1265G>A variant is predicted to result in the amino acid substitution p.Arg422Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |